BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Harvard Business School
US Department of Justice
Fish and Richardson
Boehringer Ingelheim

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206011

« Back to Dashboard

NDA 206011 describes ATRACURIUM BESYLATE, which is a drug marketed by Aurobindo Pharma Ltd, Baxter Hlthcare, Baxter Hlthcare Corp, Hospira, Hospira Inc, Mylan Labs Ltd, Nanjing King-friend, Teva Parenteral, Watson Pharms Teva, West-ward Pharms Int, and Watson Labs Inc, and is included in twenty-two NDAs. It is available from five suppliers. Additional details are available on the ATRACURIUM BESYLATE profile page.

The generic ingredient in ATRACURIUM BESYLATE is atracurium besylate. There are sixteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the atracurium besylate profile page.
Summary for 206011
Applicant:Aurobindo Pharma Ltd
Ingredient:atracurium besylate
Formulation / Manufacturing:see details
Pharmacology for NDA: 206011
Medical Subject Heading (MeSH) Categories for 206011
Suppliers and Packaging for NDA: 206011
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATRACURIUM BESYLATE atracurium besylate INJECTABLE;INJECTION 206011 ANDA AuroMedics Pharma LLC 55150-217 55150-217-10 10 VIAL, MULTI-DOSE in 1 CARTON (55150-217-10) > 10 mL in 1 VIAL, MULTI-DOSE
ATRACURIUM BESYLATE atracurium besylate INJECTABLE;INJECTION 206011 ANDA Aurobindo Pharma Limited 65862-985 65862-985-10 10 VIAL, MULTI-DOSE in 1 CARTON (65862-985-10) > 10 mL in 1 VIAL, MULTI-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength10MG/ML
Approval Date:Apr 8, 2015TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Federal Trade Commission
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.